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Wang et al., page 40
Nearly 10% of all childhood blindness is caused by ocular
coloboma, the abnormal or incomplete fusion of the optic
fissure. Proper eye development requires the careful
spatiotemporal orchestration of numerous transcription
factors and signaling molecules. As such, there are many
possible missteps that can occur prior to the fusion event.
Although much research has been done that aims at iden-
tifying the genetic underpinnings of coloboma, the cause
is known for only about half of the diagnosed cases. In
this issue, Wang et al. show that mutations in ABCB6
cause ocular coloboma. In addition to finding patient-
derived mutations, experiments in zebrafish show that
decreased Abcb6 expression results in developmental delay
and coloboma-like phenotypes. ABCB6 is a member of the
ABC family of transporters; it is thought to function in
iron metabolism and/or homeostasis. In addition to pro-
viding insight into the genetic and molecular underpin-
nings of coloboma, this finding lends further support to
the idea that dysregulation of metal ions underlies ocular
disorders. The ability to screen zebrafish for a variety of
optical malformations suggests that it should be possible
to test this hypothesis with both forward and reverse
genetics.Figuring Out Fats
Basel-Vanagaite et al., page 49
By now, we all know that a high fat diet increases the
likelihood of developing numerous health problems,
including obesity and coronary artery disease. For some
people, however, elevated triglyceride levels are caused
by genetics, not fast food. Unfortunately, the causes of
hereditary hyperglyceridemia are known in less than 5%
of cases. In this issue, Basel-Vanagaite et al. identify homo-
zygous splice-site mutations in glycerol-3 phosphate dehy-
drogenase (GPD1) in a rare form of hypertriglyceridemia
that affects infants and predisposes them to cirrhosis.
GPD1 is an enzyme with a known role in glycerol metabo-
lism, but to date, defects in its function have not been
implicated in human disease. Specifically, GPD1 is required
for the transportation of reducing equivalents from
the cytoplasm to the mitochondria. Expression of this
mutant version of GPD1 increased triglyceride secretion1Deputy Editor, AJHG
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Thein cultured cells, thus providing a launching pad for future
mechanistic studies and clinical interventions. Although
the hyperglyceridemia is transient in this disorder, tackling
the elevated triglycerides early on could prevent several
related health problems that develop later in life—
although they still might want to steer clear of hamburgers
and fries.Uncovering a Signaling Web
Mitchell et al., page 69
and Kalay et al., page 76
Pterygium sydromes comprise a group of congenital disor-
ders typified by skin webs and craniofacial anomalies.
Although causative mutations have been identified for
some of these disorders, the underlying genetic cause of
Bartsocas-Papas syndrome remained elusive because of
early lethality in affected individuals. Through homozy-
gosity mapping and exome sequencing, Kalay et al. and
Mitchell et al., respectively, have uncovered mutations
that cause this disorder and in so doing have increased
our understanding of basic skin biology. Both groups iden-
tified heterozygous RIPK4 mutations in affected individ-
uals. A kinase that activates the NF-kB and JNK pathways,
RIPK4 was known to play a role in keratinocyte differenti-
ation, but questions remained regarding its regulation.
Satisfyingly, Mitchell et al. gained additional insight into
the mechanism by which RIPK4 influences skin develop-
ment by showing that DNp63a, a master regulator of
epithelial development, directly regulates RIPK4 transcrip-
tion. DNp63a also activates IRF6 and IKKA, genes mutated
in related disorders, pointing to the existence of a nodal
point in the genesis of an even wider range of pterygium
syndromes. These studies therefore provide crucial infor-
mation to clinicians, but also should attract the attention
of basic biologists studying skin development and inflam-
matory responses.X Marks the Spot
Lederer et al., page 119
Long recognized as enforcing an extra layer of gene regu-
lation, altered histone modifications have been impli-
cated in mediating several key developmental processes.
Not surprisingly, then, several enzymes involved in the
deposition and removal of histone modifications haveGenetics. All rights reserved.
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been implicated in tumorigenesis and cancer progression.
How the placement of these marks translates to other
human diseases, however, is just starting to be appreci-
ated. Mutations in MLL2, which encodes a histone
methyltransferase, cause over half of the cases of Kabuki
syndrome, typified by developmental delay and diverse
congential anomalies. In this issue, Lederer et al. show
that microdeletions encompassing KDM6A, a gene located
on the X chromosome, can also cause Kabuki syndrome.
KDM6A demethylates mono-, di-, and tri-methylated
histone H3K27, events implicated in diverse develop-
mental processes. Interestingly, MLL2 and KDM6A are
interaction partners, pointing to the possibility that
although Kabuki syndrome is a genetically heterogeneous
disorder, a single disrupted cellular pathway might be
to blame. Overall, these findings highlight the increas-
ingly appreciated importance of histone methylation/
demethylation in intellectual disability syndromes, and
suggest that genes encoding related enzymes might be
good candidates for future sequencing studies in this
family of disorders. Moreover, given that cancer is not
a characteristic feature of Kabuki syndrome, the described
roles of MLL2 and KDM6A as tumor suppressors suggests
that we really are only just beginning to understand
the complex nature of histone modifications in human
disease.2 The American Journal of Human Genetics 90, 1–2, January 13, 2012Another Piece in the ASD Puzzle
Vaags et al., page 133
With nearly 1 in 110 children affected by autism spectrum
disorder (ASD), the race is on to identify and understand
the underlying genetic factors. Indeed, de novo and rare
inherited CNVs, along with point mutations, have been
identified in several genes. However, the picture is far
from complete, as one might expect from such a complex
group of disorders. In this issue, Vaags and colleagues find
rare, inherited microdeletions at the NRXN3 locus. Inter-
estingly, the nature of the deletion seems to correlate
with the severity of ASDphenotypes. Specifically, this locus
encodes two NRXN3 isoforms, and individuals harboring
deletions affecting both isoforms displaymore severe forms
of ASD. Additionally, the authors’ sequencing efforts iden-
tified severalmissensemutations (in different genes) which
could represent potential modifiers. NRXN3 belongs to the
neurexin family, a group of proteins known to perform
important functions in the brain. Previous studies have
pointed to a role for NRXN1 and NRXN2 alterations in
ASD, and so these latest findings highlight that this
pathway, when dysregulated, can lead to ASD. Although
the work is far from over, this latest report provides impor-
tant insights on the biology of these disorders which affect
an ever-increasing number of families.
